WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406757
CAS#: 403811-55-2
Description: 10058-F4 is a potent and selective c-Myc inhibitor, which markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells. 10058-F4 inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. 10058-F4 induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
MedKoo Cat#: 406757
Name: 10058-F4
CAS#: 403811-55-2
Chemical Formula: C12H11NOS2
Exact Mass: 249.0282
Molecular Weight: 249.346
Elemental Analysis: C, 57.80; H, 4.45; N, 5.62; O, 6.42; S, 25.72
Synonym: 10058-F4; 10058F4; 10058 F4.
IUPAC/Chemical Name: 5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone
InChi Key: SVXDHPADAXBMFB-JXMROGBWSA-N
InChi Code: InChI=1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+
SMILES Code: O=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S
Appearance: Yellow solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 249.346 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zhang M, Fan HY, Li SC. Inhibition of c-Myc by 10058-F4 induces growth arrest
and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed Pharmacother.
2015 Jul;73:123-8. doi: 10.1016/j.biopha.2015.05.019. Epub 2015 Jun 1. PubMed
PMID: 26211592.
2: Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J, Jin J. 10058-F4, a c-Myc
inhibitor, markedly increases valproic acid-induced cell death in Jurkat and
CCRF-CEM T-lymphoblastic leukemia cells. Oncol Lett. 2014 Sep;8(3):1355-1359.
Epub 2014 Jun 24. PubMed PMID: 25120723; PubMed Central PMCID: PMC4114592.
3: Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max
disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in
mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi:
10.1007/s00280-008-0774-y. Epub 2008 May 29. PubMed PMID: 18509642; PubMed
Central PMCID: PMC2752825.
4: Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor,
10058-F4, inhibits proliferation, downregulates human telomerase reverse
transcriptase and enhances chemosensitivity in human hepatocellular carcinoma
cells. Anticancer Drugs. 2007 Feb;18(2):161-70. PubMed PMID: 17159602.
5: Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor,
10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of
human acute myeloid leukemia. Exp Hematol. 2006 Nov;34(11):1480-9. PubMed PMID:
17046567.
